Study guide

5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium

Key Takeaways Explain This Topic AI

Severe hyperkalaemia (K+ ≥6.5 mmol/L or any level with ECG changes) mandates an immediate 3-step protocol: Step 1 myocardial membrane stabilisation (IV calcium gluconate/chloride), Step 2 intracellular shifting (IV insulin-dextrose and nebulised salbutamol), and Step 3 elimination (potassium binders, loop diuretics, or emergent haemodialysis).

Hypokalaemia causes muscle weakness and cardiac arrhythmias with characteristic ECG findings (T-wave flattening, ST depression, prominent U waves); correction requires oral KCl for mild cases or cautious IV KCl infusions (max 10–20 mmol/h), with mandatory correction of concurrent hypomagnesaemia.

Hyponatraemia (Na <135 mmol/L) requires systematic classification by osmolality and volume status to identify hypovolaemic (GI/renal loss -> 0.9% saline), euvolaemic (SIADH -> fluid restriction), and hypervolaemic (heart failure/cirrhosis -> fluid restriction/diuretics) states; correction must never exceed 8–10 mmol/L in 24 hours to avert Osmotic Demyelination Syndrome.

Severe hypercalcaemia (adjusted Ca >3.0 mmol/L, primarily caused by primary hyperparathyroidism or malignancy) presents with 'bones, stones, abdominal groans, psychiatric moans'; emergency initial management requires aggressive IV 0.9% saline rehydration (3–4 L in 24h) followed by intravenous bisphosphonates (zoledronic acid).

Last updated: October 2026

Electrolyte Emergencies: Potassium, Sodium & Calcium

Electrolyte disturbances are ubiquitous across acute hospital admissions. Because potassium, sodium, and calcium govern transmembrane action potentials, neuromuscular transmission, and osmotic fluid distribution, severe derangements precipitate lethal cardiac arrhythmias, seizures, and cerebral herniation unless treated systematically.

1. Hyperkalaemia: Diagnostic Stratification & Emergency Management

Serum potassium is normally maintained within a narrow physiological range of 3.5–5.0 mmol/L by renal potassium excretion (driven by aldosterone in the cortical collecting tubule) and cellular buffering (Na+/K+-ATPase pump driven by insulin and beta-2 adrenergic stimulation).

  • Severity Classification (UK Kidney Association & Resuscitation Council UK / RCUK Guidelines)
  • Mild Hyperkalaemia: 5.5–5.9 mmol/L
  • Moderate Hyperkalaemia: 6.0–6.4 mmol/L

Severe Hyperkalaemia: ≥ 6.5 mmol/L (OR any potassium elevation accompanied by electrocardiographic changes; this is a medical emergency!)

Electrocardiographic (ECG) Progression

As extracellular potassium rises, resting membrane potential partially depolarises, inactivating sodium channels and accelerating repolarisation. The ECG changes progress sequentially:

Tall, tented / peaked T waves: Narrow base, symmetrical, prominent in precordial leads (earliest sign).

P-wave flattening & PR prolongation: P waves widen and disappear; PR interval lengthens.

QRS complex widening: Intraventricular conduction delay; QRS widens and merges with the T wave.

Sine-wave pattern: Severe conduction block; pre-terminal rhythm.

Cardiac arrest: Degeneration into ventricular fibrillation (VF), pulseless electrical activity (PEA), or asystole.

The Three-Step Emergency Management Protocol

Step Primary Therapeutic Objective Intervention & Regimen Onset & Duration Critical Clinical Facts

Step 1: Stabilise Myocardial cell membrane stabilisation IV Calcium Gluconate 10% 10–30 mL over 5–10 min (OR IV Calcium Chloride 10% 5–10 mL in cardiac arrest or shock) Onset: 1–3 minutes ; Duration: 30–60 minutes Does NOT lower serum potassium! Antagonises membrane excitability to prevent VF. Repeat ECG at 5 min; if changes persist, repeat dose.

Step 2: Shift Intracellular shifting of potassium 1. 10 units soluble insulin (Actrapid) with 25 g glucose (UK Kidney Association: 125 mL 20% glucose, or 50 mL 50% glucose) IV over 15 min; if pre-treatment glucose is below 7 mmol/L, follow with 10% glucose at 50 mL/h for 5 hours; 2. Nebulised Salbutamol 10–20 mg Insulin: onset 15 min, lasts 4–6h; Salbutamol: onset 30 min, lasts 2–4h Insulin stimulates Na+/K+-ATPase. Monitor capillary blood glucose hourly for 6h (high risk of delayed hypoglycemia). Salbutamol is synergistic but causes tachycardia.

Step 3: Eliminate Total body potassium elimination 1. Oral Sodium Zirconium Cyclosilicate (Lokelma) 10 g TDS OR Patiromer 8.4 g OD; 2. IV Furosemide 40–80 mg (if non-oliguric); 3. Emergency Haemodialysis Binders: onset 1–2 hours; Dialysis: immediate clearance Lokelma exchanges K+ for Na+/H+ in the GI tract. Haemodialysis is definitive for refractory hyperkalaemia or end-stage kidney disease.

Warning

Rule Out Pseudohyperkalaemia: Marked in-vitro haemolysis from prolonged tourniquet application, fist clenching during venepuncture, or delayed laboratory centrifugation falsely elevates potassium. However, if the patient has risk factors (AKI, CKD, missed dialysis) or toxic ECG changes, never delay treatment to await a repeat sample!

2. Hypokalaemia: Pathophysiology & Safe Replacement

Hypokalaemia is defined as serum potassium < 3.5 mmol/L (severe if < 2.5–3.0 mmol/L ).

Aetiologies: Gastrointestinal loss (prolonged vomiting, diarrhoea, laxative abuse, VIPoma), renal wasting (loop or thiazide diuretics, primary hyperaldosteronism / Conn's syndrome, Cushing's syndrome, Renal Tubular Acidosis Types 1 and 2), transcellular shift (acute alkalosis, refeeding syndrome, excess insulin, salbutamol toxicity), and hypomagnesaemia .

ECG Manifestations: Flattening or inversion of T waves, ST-segment depression, prominent U waves (positive deflection immediately following the T wave, prominent in leads V2–V4), prolonged PR interval, and ventricular arrhythmias (Torsades de Pointes).

Replacement Protocol:

Mild Hypokalaemia (3.0–3.4 mmol/L, asymptomatic): Oral replacement with potassium chloride tablets (e.g. Sando-K, 2–4 tablets daily in divided doses with food, adjusted to plasma potassium; BNF).

Severe Hypokalaemia (< 3.0 mmol/L, symptomatic, or ECG changes): Intravenous potassium chloride (KCl) infusion.

Safe IV Infusion Limits: Never exceed 10 mmol/hour in a peripheral cannula (prevents chemical phlebitis and pain). Rates up to 20 mmol/hour require a central venous catheter and continuous cardiac monitoring in an HDU/ICU setting.

FATAL DANGER: NEVER administer an undiluted IV bolus or push of potassium chloride! Rapid boluses trigger immediate refractory cardiac arrest.

MANDATORY CLINICAL RULE: Correct Hypomagnesaemia! Magnesium is a necessary cofactor for the Na+/K+-ATPase pump and physiologically inhibits the renal outer medullary potassium (ROMK) channels. In hypomagnesaemia, unregulated potassium excretion into the urine occurs. Hypokalaemia is completely refractory to potassium replacement until co-existing hypomagnesaemia is corrected with IV magnesium sulphate.

3. Hyponatraemia: Diagnostic Algorithm & Safe Correction Limits

Hyponatraemia is defined as a serum sodium < 135 mmol/L (severe if < 120–125 mmol/L ). Because clinical manifestations are driven by brain cellular swelling (cerebral oedema), the speed of onset dictates severity.

  • Systematic Diagnostic Algorithm [ Serum Sodium < 135 mmol/L ]
  • │
  • [ Check Serum Osmolality ]
  • │
  • ┌─────────────────────────────────┼─────────────────────────────────┐
  • ▼ ▼ ▼
  • [ High (>295 mOsm/kg) ] [ Normal (275-295 mOsm/kg) ] [ Low (<275 mOsm/kg) ]
  • Hypertonic Hyponatraemia Pseudohyponatraemia True Hypotonic Hyponatraemia
  • Severe Hyperglycaemia • Severe Hyperlipidaemia │
  • Mannitol Infusion • Paraproteinaemia (Myeloma) │
  • [ Assess Volume Status ]
  • ┌─────────────────────────────────────┼─────────────────────────────────────┐
  • ▼ ▼ ▼
  • [ Hypovolaemic ] [ Euvolaemic ] [ Hypervolaemic ]
  • Dry mucosa, low JVP, postural drop Normal JVP, no oedema Elevated JVP, oedema, ascites
  • │ │ │
  • [ Check Urine Na ] [ Check Urine Na & Osm ] [ Heart Failure, Cirrhosis, ]
  • ┌─────────────┴─────────────┐ │ [ Nephrotic Syndrome ]
  • ▼ ▼ ▼ │
  • [ Urine Na < 20 ] [ Urine Na > 20 ] [ Urine Na >30, Osm >100 ] [ Fluid Restriction & ]
  • Extra-renal loss: Renal loss: SIADH [ Loop Diuretics ]
  • Vomiting, Diarrhoea Diuretics, Addison's • Small cell lung cancer
  • │ │ • Stroke, Trauma, Meningitis
  • [ IV 0.9% Saline ] [ IV 0.9% Saline ] • SSRIs, Carbamazepine, PPIs
  • │
  • [ Fluid Restriction 500-1000 mL ]
  • The Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

SIADH is the most common cause of euvolaemic hyponatraemia. Excessive unsuppressed ADH (arginine vasopressin) acts on renal V2 receptors in collecting ducts, driving unregulated water reabsorption.

Diagnostic Criteria: Hypotonic hyponatraemia (<275 mOsm/kg), inappropriately concentrated urine ( urine osmolality > 100 mOsm/kg , typically >300), natriuresis ( urine sodium > 30 mmol/L due to volume-expansion driven ANP release), clinical euvolaemia, and normal thyroid, adrenal, and renal function.

Common Triggers: Malignancy (small cell lung carcinoma #1), chest disorders (pneumonia, tuberculosis, lung abscess), central nervous system disorders (stroke, subdural haematoma, meningitis), and drugs (SSRIs, carbamazepine, cyclophosphamide, PPIs).

Management: Fluid restriction to 500–1000 mL/24 hours is first-line. Oral sodium chloride tablets, urea, or vasopressin receptor antagonists (vaptans, e.g. tolvaptan) are second-line for refractory cases.

Rate of Correction & Osmotic Demyelination Syndrome

When hyponatraemia develops chronically (>48 hours), cerebral astrocytes adapt to hypoosmolality by expelling intracellular organic osmolytes (glutamate, myo-inositol, taurine) to attenuate cellular swelling.

Maximum Correction Rate: NEVER exceed 8–10 mmol/L in 24 hours (or 18 mmol/L in 48 hours). In high-risk patients (alcohol dependency, malnutrition, advanced liver disease), limit correction to ≤ 6–8 mmol/L in 24 hours .

Osmotic Demyelination Syndrome (ODS / Central Pontine Myelinolysis): Rapid correction causes sudden extracellular hyperosmolality. Water rapidly rushes out of brain cells, collapsing astrocytes and precipitating demyelination of oligodendrocytes in the pons. Manifests 2–6 days post-correction with dysarthria, dysphagia, horizontal gaze paralysis, spastic quadriparesis, and irreversible "locked-in" syndrome .

Severe Symptomatic Hyponatraemia (Seizures / Coma): Administer hypertonic 3% sodium chloride bolus (150 mL IV over 20 minutes; repeat once if needed) to achieve a rapid target rise of 4–6 mmol/L in serum sodium, reversing fatal brain herniation, and then immediately stop hypertonic infusions.

4. Hypercalcaemia: Evaluation & Resuscitation Protocol

Normal serum adjusted calcium is 2.20–2.60 mmol/L (severe if > 3.0–3.5 mmol/L ).

Aetiology: Over 90% of cases are attributable to either primary hyperparathyroidism (80% of ambulatory cases; solitary parathyroid adenoma #1; elevated or inappropriately normal PTH, elevated calcium, low phosphate) or malignancy (most common inpatient cause; PTHrP production in squamous cell lung or renal cancer, osteolytic metastases in breast cancer or multiple myeloma; suppressed PTH).

Clinical Presentation: Classically memorised as "bones, stones, abdominal groans, and psychiatric moans" :

Bones: Bone pain, osteopenia, pathological fractures.

Stones: Nephrolithiasis, nephrocalcinosis, polyuria, and polydipsia (nephrogenic diabetes insipidus).

Abdominal Groans: Anorexia, nausea, severe constipation, peptic ulcer disease, acute pancreatitis.

Psychiatric Moans: Fatigue, depression, delirium, acute psychosis, coma.

Cardiac: Shortened QT interval on ECG, predisposing to fatal arrhythmias.

Acute Emergency Resuscitation

First-Line Intervention: Aggressive Intravenous Rehydration: Administer intravenous 0.9% normal saline at 3 to 4 litres over 24 hours (guided by cardiovascular status and urine output). Hypercalcaemic patients are profoundly dehydrated from polyuria and vomiting; rehydration restores renal perfusion and promotes urinary calcium excretion (calciuresis).

Second-Line Pharmacotherapy: Intravenous Bisphosphonates: Administer zoledronic acid 4 mg IV over 15 minutes (or pamidronate 30–90 mg IV). Bisphosphonates inhibit osteoclastic bone resorption. Exam Key: Bisphosphonates exhibit a delayed onset of action ( takes 48 to 72 hours to lower calcium, with nadir effect at 4–6 days); they do not work acutely!

Adjunctive Therapies:

Calcitonin (SC/IM): Produces a rapid reduction in calcium within 2–4 hours; useful as an acute bridge while awaiting bisphosphonate efficacy, but tachyphylaxis occurs within 48 hours.

Glucocorticoids (oral prednisolone 20–40 mg daily): First-line for hypercalcaemia driven by calcitriol overproduction in sarcoidosis , lymphoma, or vitamin D toxicity.

Denosumab: Monoclonal antibody against RANKL, indicated in refractory hypercalcaemia of malignancy or when bisphosphonates are contraindicated by severe renal failure.

Loading diagram... Hyperkalaemia Emergency Resuscitation Algorithm